Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | GLP1R | P43220 | 8/20 | 0.53 |
| ▸ | ALB | P02768 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | GNPAT | O15228 | 1/20 | 0.49 |
| ▸ | FNTA | P49354 | 1/20 | 0.46 |
| ▸ | FNTB | P49356 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21078712 | 1.00 | NOD1 (0.56) | NOD1FOLH1GLP1RALBEPHX2 | |
| SCHEMBL13057101 | 0.92 | FOLH1 (0.55) | NOD1FOLH1GLP1RALBEPHX2 | |
| SCHEMBL22756226 | 0.91 | NOD1 (0.68) | NOD1GLP1REPHX2 | |
| SCHEMBL25850271 | 0.88 | GLP1R (0.57) | NOD1FOLH1GLP1RALBEPHX2 | |
| SCHEMBL21099881 | 0.88 | NOD1 (0.57) | NOD1FOLH1GLP1REPHX2FNTA | |
| SCHEMBL21099650 | 0.88 | NOD1 (0.57) | NOD1FOLH1GLP1REPHX2FNTA | |
| SCHEMBL16259353 | 0.88 | NOD1 (0.71) | NOD1GLP1REPHX2 | |
| SCHEMBL16259357 | 0.88 | NOD1 (0.71) | NOD1GLP1REPHX2 | |
| SCHEMBL16259359 | 0.88 | NOD1 (0.71) | NOD1GLP1REPHX2 | |
| SCHEMBL20162097 | 0.88 | NOD1 (0.71) | NOD1GLP1REPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040171-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ACYLATED DERIVATIVE OF HUMAN INSULIN ANALOG AND PREPARATION METHOD THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-02-11 | — | — | US | disclosed |
| EP-3747896-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ACYLATED DERIVATIVE OF HUMAN INSULIN ANALOG AND PREPARATION METHOD THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2020-12-09 | — | — | EP | disclosed |
| US-10815287-B2 | Acylated derivative of human insulin or analogue thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-10-27 | — | — | US | disclosed |
| WO-2019149245-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ACYLATED DERIVATIVE OF HUMAN INSULIN ANALOG AND PREPARATION METHOD THEREOF | 江苏恒瑞医药股份有限公司 | 2019-08-08 | — | — | WO | disclosed |
| EP-3495384-A1 | ACYLATED DERIVATIVE OF HUMAN INSULIN OR ANALOGUE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2019-06-12 | — | — | EP | disclosed |
| US-20190169257-A1 | ACYLATED DERIVATIVE OF HUMAN INSULIN OR ANALOGUE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040171-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ACYLATED DERIVATIVE OF HUMAN INSULIN ANALOG AND PREPARATION METHOD THEREOF | IAPP, INSR, GPR119 | NOD1 1783/4885FOLH1 2684/4885GLP1R 13/4885 |
| US-10815287-B2 | Acylated derivative of human insulin or analogue thereof | INSR, IAPP, HDAC10 | NOD1 3795/4885FOLH1 3694/4885GLP1R 114/4885 |
| US-20190169257-A1 | ACYLATED DERIVATIVE OF HUMAN INSULIN OR ANALOGUE THEREOF | IAPP, INSR, GPR119 | NOD1 4337/4885FOLH1 3167/4885GLP1R 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.